Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total revenue $ 508 $ 240 $ 1,047 $ 370
Costs of revenue 104 66 222 146
Gross profit 404 174 825 224
Operating expenses:        
Research and development 2,148 1,476 4,364 3,128
General and administrative 1,168 993 2,323 1,849
Sales and marketing 308 338 618 732
Grant and contract expenses 244 150 540 176
Total operating expenses 3,868 2,957 7,845 5,885
Loss from operations (3,464) (2,783) (7,020) (5,661)
Other income (expenses):        
Interest expense (2) (8)
Interest income 47 2 84 3
Loss on disposal of assets (1) (1)
Change in fair value of derivative liabilities 965 108 4,971 148
Offering costs of derivative liabilities (786)
Other income, net (3) 162 5 162
Total other income (expense), net 1,009 271 4,272 304
Net loss before income taxes (2,455) (2,512) (2,748) (5,357)
Provision for income taxes
Net loss (2,455) (2,512) (2,748) (5,357)
Deemed dividend related to convertible preferred stock (26) (26)
Net loss attributable to common stockholders $ (2,481) $ (2,512) $ (2,774) $ (5,357)
Net loss per share – basic and diluted        
Basic – net loss $ (0.60) $ (10.16) $ (0.87) $ (21.68)
Basic – deemed dividend on conversion of preferred stock (0.01) (0.01)
Basic – attributable to common stockholders (0.61) (10.16) (0.88) (21.68)
Diluted – net loss (0.77) (10.45) (2.23) (21.95)
Diluted - deemed dividend on conversion of preferred stock (0.01) (0.01)
Diluted – attributable to common stockholders $ (0.78) $ (10.45) $ (2.24) $ (21.95)
Weighted average common shares outstanding:        
Basic 4,070,195 247,166 3,176,558 247,144
Diluted 4,436,613 250,787 3,282,667 250,806
Product [Member]        
Total revenue $ 235 $ 80 $ 475 $ 181
Grant and Contract [Member]        
Total revenue $ 273 $ 160 $ 572 $ 189